Sustained Viral Response Rate in 50 Subjects With Cirrhosis Due to Hepatitis C, Genotype 1, Treated With 12 Weeks of Sofosbuvir, Ledipasvir and Ribavirin

Trial Profile

Sustained Viral Response Rate in 50 Subjects With Cirrhosis Due to Hepatitis C, Genotype 1, Treated With 12 Weeks of Sofosbuvir, Ledipasvir and Ribavirin

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary) ; Sofosbuvir (Primary) ; Ledipasvir; Ribavirin
  • Indications Liver cirrhosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2017 Planned End Date changed from 1 Jan 2017 to 1 Oct 2017.
    • 05 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2017.
    • 05 Apr 2017 Status changed from not yet recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top